BioSpace News Archive

Baxter International Inc., a global medtech leader, announced that its Board of Directors has declared a quarterly cash dividend of $0.28 per share of common stock.

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced its financial and operational results for the third quarter of its fiscal year 2022, which ended on December 31, 2021.

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive data from the company’s late-stage bladder cancer trial (QUILT-3.032).

Veracyte, Inc. (Nasdaq: VCYT) announced that new data validating the clinical utility of the company’s Decipher Prostate Genomic Classifier for guiding treatment selection in men with intermediate-risk prostate cancer will be presented Thursday, February 17, at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Symposium (Poster #M1).

Jiangsu Recbio Technology Co., Ltd., a China-based company focused on the development of innovative vaccines for major diseases, announced preclinical data of its subsidiary Wuhan Recogen Biotechnology Co., Ltd. on lyophilized mRNA vaccine.

PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced positive five-year results from its 181 patient randomized WATER study comparing Aquablation therapy to TURP, the historical standard of care for treating BPH.

Rubius Therapeutics, Inc. (Nasdaq: RUBY), today announced plans to report fourth quarter and full year 2021 financial results on Friday, February 25, 2022, before market open.

Omnicell, Inc., a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, announced results for its fourth quarter and fiscal year ended December 31, 2021.

Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported its financial results for the fiscal year ended December 31, 2021.

Omnicell, Inc. announced that UMC Health System in Lubbock, Texas, has selected Omnicell’s comprehensive portfolio of Advanced Services solutions to support key pharmacy initiatives, including acute care, outpatient, retail, and 340B program strategies.